Halozyme Therapeutics, Inc. · Brief

Next report

5 days

Nov 5 · after closeconfirmedQ3 FY26

Expected move

±4.8%implied · report alone

124.68137.14

straddle ±7.6%

spot 130.91exp Nov 20ATM strike 130ATM straddle 11.70IV 47%

Oct 30 closereport share · term structure

Expected move

—≥ implied

Q2 FY26±6.0%▲+20.24%×3.37

quarterimplied−25%0+25%realized×

Q2 FY26±6.0%▲+20.24%×3.37

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 5 report · confirmed

Bull2 of 4

2customers disclosing it as a supplierSEC filings

4tracked funds holding the stockN-PORT · Jul 31 '26

Bear2 of 3

7 of 24largest reporting managers that cut their stake in the latest quarter13F · Jun 30 '26

−0.59%change in shares held by the largest reporting managers over the latest quarter13F · Jun 30 '26

AI captions · Oct 26 '26once per report · top 2 per case

HALO report session

No linked exposure.

Oct 22impliedImplied move: ±8.4% into Nov 5 earnings (Oct 22 close).Source

Oct 22report dateEarnings date confirmed: Nov 5, after close.Source

Oct 19impliedImplied move: ±9.0% into Nov 2 earnings (Oct 19 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.